Thomas James Doyle
Known title: SVP, Finance & AccountingCIK: 0001910331
Associated companies
Transaction History
| KURA | ▼ Sell | Open Market | 695 | $6K | 1/27/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 2,226 | $19K | 1/27/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 881 | $7K | 1/27/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 2,226 | $19K | 1/27/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 1,114 | $9K | 1/27/2026 | View on chart |
| KURA | ▲ Buy | Grant | 21,250 | $0 | 1/2/2026 | View on chart |
| KURA | ▼ Sell | Open Market | 4,539 | $51K | 11/14/2025 | View on chart |
| KURA | ▲ Buy | Grant | 24,967 | $0 | 11/13/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project
Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.
Kura Oncology Secures $50M for Diabetes Menin Inhibitor Project. Kura Oncology announced a $50 million partnership to develop an oral menin inhibitor for diabetes. The company will work with Caspian Therapeutics on KO‑7246, sharing data and a joint development plan. The move expands Kura’s focus beyond oncology into chronic metabolic diseases. The collaboration signals confidence in the drug’s potential for diabetes treatment.